Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer
Cancers | Free Full-Text | The Changing Paradigm for the Treatment of HER2-Positive Breast Cancer | HTML
Herceptin: mechanisms of action and resistance - ScienceDirect
Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer | British Journal of Cancer
Trastuzumab — Mechanism of Action and Use in Clinical Practice | NEJM
Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer - Annals of Oncology
Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer | Oncotarget
Frontiers | Trastuzumab: Updated Mechanisms of Action and Resistance in Breast Cancer | Oncology
References in Evolving novel anti-HER2 strategies - The Lancet Oncology
Trastuzumab: triumphs and tribulations | Oncogene
Overcoming trastuzumab resistance in HER2‐positive breast cancer using combination therapy - Derakhshani - 2020 - Journal of Cellular Physiology - Wiley Online Library
Trastuzumab (Herceptin) | American Journal of Neuroradiology
Trastuzumab
Trastuzumab in the Treatment of Breast Cancer | SpringerLink
TDM 1 Trastuzumab emtansine PreClinical and Early Clinical
View Image
Ado-trastuzumab Emtansine Overview - Creative Biolabs
Pertuzumab and Its Accelerated Approval: Evolving Treatment Paradigms and New Challenges in the Management of HER2-Positive Breast Cancer
Pertuzumab and trastuzumab: the rationale way to synergy
What is the mechanism of action of trastuzumab? - Quora
Trastuzumab emtansine: mechanisms of action and drug resistance | Breast Cancer Research | Full Text
Herceptin® (trastuzumab) for HER2+ Cancer
IJMS | Free Full-Text | Molecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast Cancer | HTML
Part:BBa K1694005 - parts.igem.org
Toxicology of Trastuzumab: An Insight into Mechanisms of Cardiotoxicity | Bentham Science
